Press Release Apr 08 2026
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Dapagliflozin Tablets in two dosages. With this approval, Zydus gains eligibility for a period of shared generic drug exclusivity for the product.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 21 2026
- Press Release Mar 19 2026
- AeroDel signs exclusive licensing arrangement with Zydus for launching Aerolife Mini™, India's First Foldable, 'Always Attached' pMDI Enhancer
- Press Release Mar 18 2026
- Press Release Mar 17 2026
Later from Zydus Lifesciences
- Press Release Apr 16 2026
- Press Release Apr 25 2026
- Press Release May 06 2026
- Press Release May 19 2026
- Zydus Cancer Hospital, Ahmedabad marks 200+ Stereotactic Radiotherapy (SRT)/SRS for Brain Tumours
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences